|Day Low/High||187.12 / 192.63|
|52 Wk Low/High||163.31 / 210.19|
New Pledge is in Addition to $250,000 Contribution to Ventura County Community Foundation's Conejo Valley Victims Fund
Jim Cramer says the Fed is overreacting and he isn't worried about oil prices. Here's your game plan for next week.
Markets had another volatile week as trade tensions crossed currents with a U.S. midterm election that was closer than many had predicted.
Jim discusses Aimovig and Amgen, Anadarko and Schlumberger, the Federal Reserve, Disney ahead of earnings, and more!
We think defense stocks, among other sectors, can rally.
A split Congress is the best-case scenario for the drug industry, several analysts said.
Additional Analyses of Real-World Data Will Explore Treatment Utilization and Understanding of Treatment Goals in Patients at High Risk for Cardiovascular Events
Provention to Lead Phase 2b Stage of Development for Anti-IL-15 Antibody AMG 714
Jim Cramer takes a look at Microsoft, Ross Stores, Pitney Bowes, Alnylam Pharmaceuticals, Golar LNG, ResMed and more.
Jim Cramer breaks down the day's roller-coaster action amid confusing news. Plus, he's got your game plan for next week.
Stephen 'Sarge' Guilfoyle gives you a rundown of what's in his portfolio as the new month gets rolling.
First-in-Human Data Evaluating AMG 420 in Multiple Myeloma and AMG 330 in Acute Myeloid Leukemia Underscore Potential of BiTE® Immunotherapy Platform Across Hematologic Malignancies
Through a new $21 Million, Four-Year Investment, Amgen Scholars Program to Reach Additional 1,500 Undergraduates
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Jim discusses Facebook's earnings, Apple before earnings on Thursday, Anadarko Petroleum, DowDuPont, Amgen and more!
Revenue of $5.9 billion topped the consensus of $5.77 billion, and adjusted earnings per share of $3.69 exceeded the consensus of $3.45.
Jim discusses BP and Anadarko Petroleum, what to expect from Facebook earnings, the IBM and Red Hat deal, and more!
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
Overwhelmed by the earnings bonanza? Investors should be keeping an eye on when Facebook releases earnings. Listen to the podcast.
Repatha Results in Consistent Reductions in LDL-C Levels and Cardiovascular Events in Patients Independent of Kidney Function
As we did once before this week, we are treating JWN as a source of funds.
Jim Cramer weighs in on Red Hat, Take-Two Interactive, Sage Therapeutics, Mazor Robotics, Donnelly Financial Solutions.
Jim Cramer says investors need context about what's really happening with earnings, tariffs, the Fed, and in Washington.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.